News|Articles|November 22, 2026

Bentracimab Reverses Ticagrelor’s Antiplatelet Effects in Final Phase 3 REVERSE-IT Results

Listen
0:00 / 0:00

Key Takeaways

  • Bentracimab is an IgG1 antibody fragment that binds free ticagrelor and its active metabolite with ~100-fold higher affinity than P2Y12, restoring platelet function.
  • In 226 enrolled patients across 47 centers, dosing used a 6-g IV bolus, 6-g loading infusion, and 6-g maintenance infusion, with PRU inhibition and hemostasis endpoints.
SHOW MORE

Final phase 3 data showed bentracimab restored platelet function in minutes and achieved centrally adjudicated effective hemostasis in 94.3% of eligible patients, with no bentracimab-related thrombotic events reported.

Final results from the phase 3 REVERSE-IT trial (NCT04286438) showed that bentracimab (SERB Pharmaceuticals) rapidly reversed the antiplatelet effects of ticagrelor in patients requiring urgent surgery or invasive procedures or experiencing major bleeding. Treatment achieved centrally adjudicated effective hemostasis in 94.3% of eligible patients, with a safety profile the investigators described as favorable across both clinical settings.1

Senior author Subodh Verma, MD, PhD, FRCSC, FAHA, FCAHS, FCCS, professor of Surgery and Pharmacology & Toxicology at the University of Toronto, and colleagues recently presented the data at the 2026 Society of Vascular and Interventional Neurology (SVIN) Annual Meeting, held November 17 to 20, in Las Vegas, Nevada. Bentracimab is a recombinant human IgG1 monoclonal antibody fragment designed to restore platelet function by selectively binding free ticagrelor and its active metabolite with 100-fold greater affinity than either has for the P2Y12 receptor.1

Ticagrelor is used to treat patients with acute coronary syndromes, prior myocardial infarction, high-risk coronary artery disease, transient ischemic attack, or ischemic stroke.3 According to the presentation, current options for patients on antiplatelet therapy who require urgent surgery or experience major bleeding are limited and often ineffective.1

REVERSE-IT was a multicenter, open-label, single-arm, prospective trial that enrolled 226 ticagrelor-treated patients across 47 centers in North America, Europe, and China. Of these, 212 were centrally adjudicated as eligible, including 141 who underwent urgent surgery and 71 who experienced uncontrolled major or life-threatening bleeding. Patients received a 6-g intravenous bolus of bentracimab over 10 minutes, followed by a 6-g loading infusion over 4 hours and a 6-g maintenance infusion over 12 hours. The primary end point was the minimum percent inhibition of P2Y12 reaction units (PRU) in 4 hours of bentracimab initiation, measured with the VerifyNow assay. The key secondary end point was centrally adjudicated effective hemostasis in 24 hours.1

Rapid Reversal and Hemostasis Across Subgroups

Mean percent inhibition of PRU fell from 48.6% (95% CI, 42.8%-54.4%) before dosing to −74.4% (95% CI, −78.6% to −70.1%) in 4 hours, a mean difference of −122.9 (95% CI, −129.2 to −116.7; P <.0001). Results were consistent in the urgent surgery (−124.6) and major bleeding (−120.3) subgroups. Mean PRU rose from 92 before treatment to 242 at 5 to 10 minutes and remained between 242 and 297 through 24 hours.1

READ MORE: Perfuze Receives FDA Clearance for NeuroSheath 8F Long Sheath

Effective hemostasis was achieved in 200 of 212 eligible patients (94.3%; 95% CI, 87.6%-100%; P <.0001), including all 141 patients in the surgery group (100%; 95% CI, 91.7%-100%) and 59 of 71 patients in the major bleeding group (83.1%; 95% CI, 71.5%-94.7%).1

Overall, 25.7% of enrolled patients required at least 1 blood product, including 7.8% of the surgery group and 60.6% of the bleeding group; the investigators reported a median of 1 unit of packed red blood cells and/or platelets in each group. Median hospital stay was 10 days (IQR, 7-14), and 76.5% of patients were discharged home. Median time to start or restart any P2Y12 inhibitor was 2 days.1

Safety Findings

At least 1 treatment-emergent adverse event (TEAE) was reported in 87.2% of patients, and 4 patients (1.8%) had a bentracimab-related TEAE; these were mild or moderate and resolved. Treatment-emergent and posttreatment serious adverse events occurred in 14.2% and 21.2% of patients, respectively, none of which were considered related to bentracimab. Nine patients (4%) had adverse events leading to death, none considered related to treatment. Adverse events of special interest, which included postreversal thrombotic events, occurred in 8 patients (3.5%); none were bentracimab-related or led to death. No serious infusion-related, allergic, or anaphylactic reactions occurred, and antibentracimab antibodies did not affect efficacy end points.1

The final results build on a phase 1 study in healthy volunteers, in which bentracimab reversed ticagrelor in 5 minutes with effects sustained for more than 20 hours,2 and a prespecified interim analysis of REVERSE-IT, in which adjudicated hemostasis was achieved in more than 90% of 122 evaluable patients, most of whom required urgent surgery.3 A 2026 review noted that because REVERSE-IT lacked a comparator arm, a full assessment of efficacy is not possible.4

Portions of the data were previously presented at the American College of Cardiology 2025 meeting. REVERSE-IT was initially funded by PhaseBio and later by SFJ Pharmaceuticals; SERB Pharmaceuticals acquired exclusive US rights to bentracimab.1

Click here for more of our SVIN 2026 coverage.

REFERENCES
1. Lim P, Bhatt DL, Pollack CV Jr, et al; REVERSE-IT Investigators. REVERSE-IT final results: bentracimab reversal of ticagrelor in major bleeding or urgent surgery or procedure. Presented at: 2026 Society of Vascular and Interventional Neurology Annual Meeting; November 17-20, 2026; Las Vegas, NV.
2. Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med. 2019;380(19):1825-1833. doi:10.1056/NEJMoa1901778
3. Bhatt DL, Pollack CV, Mazer CD, et al. Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery. NEJM Evid. 2022;1(3):EVIDoa2100047. doi:10.1056/EVIDoa2100047
4. Maynard S, Bye AP, Desborough MJR. Can drug-induced platelet dysfunction be reversed?. Res Pract Thromb Haemost. 2025;10(1):103286. Published 2025 Dec 9. doi:10.1016/j.rpth.2025.103286

Related to this article